Scorpius Holdings Faces Delisting Concerns
Ticker: SCPX · Form: 8-K · Filed: Apr 22, 2024 · CIK: 1476963
| Field | Detail |
|---|---|
| Company | Scorpius Holdings, Inc. (SCPX) |
| Form Type | 8-K |
| Filed Date | Apr 22, 2024 |
| Risk Level | high |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0002 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-rule, company-name-change
Related Tickers: SCPX
TL;DR
SCPX might get delisted, watch out!
AI Summary
Scorpius Holdings, Inc. (SCPX) filed an 8-K on April 22, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The earliest event reported was on April 17, 2024. The company was formerly known as NightHawk Biosciences, Inc. and HEAT BIOLOGICS, INC.
Why It Matters
This filing indicates potential issues with Scorpius Holdings' continued listing on a stock exchange, which could significantly impact its stock price and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a significant risk to investors.
Key Players & Entities
- Scorpius Holdings, Inc. (company) — Registrant
- SCPX (company) — Ticker Symbol
- NightHawk Biosciences, Inc. (company) — Former Company Name
- HEAT BIOLOGICS, INC. (company) — Former Company Name
- April 17, 2024 (date) — Earliest event reported
- April 22, 2024 (date) — Filing Date
FAQ
What specific listing rule or standard has Scorpius Holdings, Inc. failed to satisfy?
The filing states 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard' but does not specify the exact rule in the provided text.
What is the earliest date of the event reported in this 8-K filing?
The earliest event reported was on April 17, 2024.
When was this 8-K filing submitted to the SEC?
The filing was submitted on April 22, 2024.
What were the previous names of Scorpius Holdings, Inc.?
The company was formerly known as NightHawk Biosciences, Inc. and HEAT BIOLOGICS, INC.
What is the primary business of Scorpius Holdings, Inc. according to the filing?
The Standard Industrial Classification code indicates the company is in 'PHARMACEUTICAL PREPARATIONS [2834]'.
Filing Stats: 1,015 words · 4 min read · ~3 pages · Grade level 15.1 · Accepted 2024-04-22 17:00:14
Key Financial Figures
- $0.0002 — nge on which registered Common Stock, $0.0002 par value per share SCPX NYSE America
Filing Documents
- scpx_8k.htm (8-K) — 32KB
- ex99x1.htm (EX-99.1) — 11KB
- image_001.jpg (GRAPHIC) — 5KB
- 0001079973-24-000581.txt ( ) — 268KB
- scpx-20240417.xsd (EX-101.SCH) — 3KB
- scpx-20240417_def.xml (EX-101.DEF) — 26KB
- scpx-20240417_lab.xml (EX-101.LAB) — 36KB
- scpx-20240417_pre.xml (EX-101.PRE) — 25KB
- scpx_8k_htm.xml (XML) — 5KB
01
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard Transfer of Listing. On April 17, 2024, Scorpius Holdings, Inc. (the "Company") received a notice (the "Notice") from the NYSE Regulation (the "Notice") stating that the Company is not in compliance with the continued listing standards of the NYSE American LLC (the "Exchange") under the timely filing criteria included in Section 1007 of the NYSE American Company Guide (the "Company Guide") because the Company failed to timely file its Annual Report on Form 10-K for the year ended December 31, 2023 (the "Delinquent Report"), which was due to be filed with the Securities and Exchange Commission (the "SEC") no later than April 16, 2024 (the "Filing Delinquency"). As previously reported in the Company's Notification of Late Filing on Form 12b-25 filed with the SEC on April 1, 2024, the Company was unable to file its Annual Report on Form 10-K for the year ended December 31, 2023 within the prescribed period because of delays experienced by the Company in preparing its consolidated financial statements. The delays relate to recent finance staff turnover of those directly involved in preparing the Delinquent Report, and the need for additional time to complete the calculation of revenue recognition for certain contracts for the year ended December 31, 2023. The Company is now subject to the procedures and requirements set forth in Section 1007 of the Company Guide . During the six month period from the date of the Filing Delinquency (the "Initial Cure Period"), the Exchange will monitor the Company and the status of the Delinquent Report and any subsequent delayed filings, including through contact with the Company, until the Filing Delinquency is cured. If the Company fails to cure the Filing Delinquency within the Initial Cure Period, the Exchange may, in its sole discretion, grant an up to six-month additional cure period (the "Additional Cure Period"). The Company can regain
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. The following exhibits are filed with this Current Report on Form 8-K: Exhibit Number Description 99.1 Press release dated April 22, 2024 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: April 22, 2024 SCORPIUS HOLDINGS, INC. By: /s/ Jeffrey Wolf Name: Jeffrey Wolf Title: Chairman, President and Chief Executive Officer